<?xml version="1.0" encoding="UTF-8"?>
<p id="p0160">Recently, a controversial observational study on the effectiveness of chloroquine or hydroxychloroquine with or without a macrolide for the treatment of COVID-19 was published. The study comprising data from over 600 hospitals in six continents concluded that chloroquine or hydroxychloroquine treatment afforded no protection to COVID-19 patients and was associated with an increased incidence of ventricular arrhythmias. However, serious questions were raised on the validity of the data published in the study. The study was later retracted from the journal as independent auditing of the data was not possible 
 <xref rid="b0645" ref-type="bibr">[129]</xref>. Reports from clinical trials like solidarity trials, RECOVERY trials have demonstrated that hydroxychloroquine offers no benefit to COVID-19 patients 
 <xref rid="b0650" ref-type="bibr">[130]</xref>, 
 <xref rid="b0655" ref-type="bibr">[131]</xref>. USFDA has also withdrawn its EUA status given to chloroquine and hydroxychloroquine in view of the recent developments 
 <xref rid="b0660" ref-type="bibr">[132]</xref>.
</p>
